Posted on 09/12/2009 in Pharmaceutical Company Product News Lilly has introduced a smaller insulin vial to the pharmaceutical market, which is indicated as a therapy for diabetes patients who are being treated in hospitals.
The new product comes in the format of a 3 ml dose (300 units) and is designed to be used alongside Lilly's exisiting Humalog (insulin lispro injection [rDNA origin]) and Humulin R-U100 (regular insulin human injection, USP [rDNA origin]) products.
With the release of the smaller insulin vials, the firm aims to offer hospitals more flexibility when evaluating their storage, delivery and distribution methods for the treatment.
Matt Beebe, insulin brand team leader at Lilly, stated: "Partnering with our institutional customers, we believe hospitals will find it to be a valuable option when evaluating their insulin storage, delivery and distribution needs."
In other Lilly news, this week the firm announced that its therapy Zyprexa (olanzapine) has been indicated for two different treatment options in adolescent patients. Other news stories from 09/12/2009
Read more in the Zenopa News Archive
How this news is generated
|
